The Roche Group posted strong operating results in the first half of 2010. Group sales grew by 5% in local currencies (3% in Swiss francs; 7% in US dollars) to 24.6 billion Swiss francs. The Pharmaceuticals Division increased its sales by 4% in local currencies (1% in Swiss francs; 6%…

As part of its commitment to improving the quality of patient care, Pfizer (NYSE: PFE) will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders.

Original Source of Pfizer to Offer Free Public…

Bristol-Myers Squibb Company (NYSE: BMY) reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS.

Original Source of Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth…

Icelandic generic drugmaker Actavis has agreed to a debt refinancing deal with its lenders to slash its multibillion-euro debt load. Release | Report

Original Source of Actavis inks key refinancing deal

It’s earnings time again, and a whole slew of drugmakers are reporting their second-quarter results. Eli Lilly beat forecasts while Elan posted a bigger net loss; Roche profits grew 58 percent on lower restructuring costs as Genzyme barely managed to stay in the black. Here are more details on…

During the congressional hearings about Johnson & Johnson’s ( NYSE: J&J ) huge children’s drug recall back in June, FDA Deputy Commissioner Joshua Sharfstein cited a “pattern of noncompliance” at McNeil Consumer Healthcare that caused the agency to step up its inspections of company plants. As details emerge about…

One of the themes emerging from this round of pharma earnings reports is Europe–specifically,

According to a congressional probe, Chinese officials sandbagged an investigation into the contaminated heparin linked to 81 deaths in late 2007 and early 2008. Texas Republicans Reps. Joe Barton and Michael Burgess say FDA officials have been “severely hampered” by China’s foot-dragging in tracing the contamination to its ultimate…

The much-debated Avandia safety trial is shutting its doors to new patients. After last week’s advisory panel meeting , the FDA has ordered GlaxoSmithKline ( NYSE: GSK )

GlaxoSmithKline [NYSE: GSK] confirmed that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA review of recommendations from its Advisory Committee meeting July 13-14.

Original Source of GlaxoSmithKline…